A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
Latest Information Update: 14 Feb 2025
At a glance
- Drugs TX-200 (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; First in man
- Acronyms STeadfast
- Sponsors Sangamo Therapeutics
Most Recent Events
- 16 Aug 2024 Planned End Date changed from 4 Mar 2026 to 29 Oct 2025.
- 24 Apr 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 24 Apr 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.